You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

Displaying 201361 - 201370 of 207725 results
  1. Novel Vitamin B6 based prodrugs of gemcitabine

    SBC: MBC Pharma, Inc.            Topic: NCI

    DESCRIPTION (provided by applicant): The long-term goal of this proposal is to develop more effective therapies for cancer, specifically pancreatic cancer. The specific focus of this proposal is to improve upon the anti-cancer activity of the drug gemcytabine. This will be accomplished by synthesizing novel conjugates of gemcytabine in a form that enables increased pathways for uptake into cancer ...

    SBIR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  2. Minimal Residual Disease Monitoring by T-cell Receptor Repertoire Profiling

    SBC: ADAPTIVE BIOTECHNOLOGIES CORPORATION            Topic: NCI

    DESCRIPTION (provided by applicant): Minimal Residual Disease Monitoring by T-cell Receptor Repertoire Profiling T-cell neoplasms are generally more aggressive and have poorer outcomes than comparable B-cell lymphomas. In addition, for many of these patients, prognosis following disease relapse is dismal. Detecting the presence or absence of Minimal Residual Disease (MRD) following treatment is em ...

    SBIR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  3. Functional Tissue Engineering for Cartilage Repair

    SBC: EXCELLIMS CORPORATION            Topic: NCI

    DESCRIPTION: The ultimate goal of the Phase I SBIR project is to establish the feasibility of using ion mobility spectrometry (IMS) or liquid chromatography-IMS (LC-IMS) as a fast, selective and sensitive method for rapid monitoring of bio manufacturing processes for on-line use to improve the understanding of the process and provide real-time feedback. Excellims will develop the LC-IMS method fo ...

    SBIR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  4. Combination immunotherapies for the treatment of melanoma

    SBC: CELDARA MEDICAL, LLC            Topic: NCI

    DESCRIPTION (provided by applicant): Melanoma is the most common form of cancer in young adults1, and its incidence is rising at a rate higher than any of the seven most common cancers2, increasing 45% between 1992 and 20043. Plexxikon and Roche are codeveloping a BrafV600E inhibitor (i.e. PLX4032 (Vemurafenib)) and BMS/Medarex recently attained FDA approval for their anti-CTLA4 antibody (i.e. ...

    SBIR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  5. NIEHS- Device Agnostic Environmental/Agent Data Collection and Integration with

    SBC: APEX Therapeuitcs, Inc.            Topic: NCI

    DESCRIPTION (provided by applicant): Our long-term goal is to develop a novel therapeutic strategy for childhood acute lymphoblastic leukemia (ALL), with focus on relapsed T-cell leukemia. We intend to accomplish this by targeting a unique molecular masterregulator using a new generation of compounds. ALL is the most frequent cancer of the childhood. Although significant progress has been achieved ...

    SBIR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  6. rAAV5-hCNGB3 Gene Therapy for Achromatopsia: Safety and Efficacy in a Dog Model

    SBC: PHusis Therapeutics Inc            Topic: NCI

    DESCRIPTION (provided by applicant): Mutant KRAS (mut-KRAS) is the prototypical undruggable cancer target. It is found in 25% of patient tumors across many cancer types and an estimated 320,000 individuals/yr who will be diagnosed with mut-KRAS in the US most of who will die of their disease. KRAS has been the single most studied human oncogene for over 30 years and yet there is no effective treat ...

    SBIR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  7. Phase II of VerOFy: A New Tool to Improve Productivity for Stress Research

    SBC: PRESAGE BIOSCIENCES, INC.            Topic: NCI

    DESCRIPTION (provided by applicant): With few exceptions, extensive characterization of signal pathway alterations in cancer, and advances in our capacity to identify potent modulators of distinct molecular targets, has not translated into breakthrough drugs. In a recent New York Times article (Nov. 14, 2009), Mervyn Turner, Chief Strategy Officer for Merck was quoted: We invest far too long in b ...

    SBIR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  8. Pharmacological Suppression of Rod Opsin as Therapy for Retinitis Pigmentosa

    SBC: ORGANIX CHEMISTRY SOLUTIONS LLC            Topic: NCI

    DESCRIPTION (provided by applicant): Metastasis of aggressive breast cancer is a devastating and ultimately fatal condition. The current first- line agents which are used to treat breast cancer metastasis primarily target tumor growth. These drugs produceonly modest increases in survival in patients with aggressive metastatic cancers and have significant side effects. Currently, there are no avail ...

    SBIR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  9. Enhanced Recovery of Pharmaceutical Solvent driven by EPA Initiative

    SBC: Planet Biotechnology Incorporated            Topic: NCI

    DESCRIPTION (provided by applicant): Antibody-dependent cellular cytotoxicity (ADCC) is an important mechanism by which therapeutic monoclonal antibodies (mAbs) kill tumor cells. However, killing by current therapeutic IgG mAbs is not optimal. InefficientADCC provides a potential escape mechanism for tumors and can be targeted to improve antibody- based cancer therapies. Most of the tumor-directe ...

    SBIR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  10. NIH Phase II-UNCD as Bio-Inert Interface for Anti-Thrombogenicity Applications in

    SBC: Lucidicor Inc.            Topic: NCI

    DESCRIPTION: Protein kinases are chemically tractable drug targets, yet less than 5% of the human kinome has been thoroughly explored with selective small molecule inhibitors to demonstrate their therapeutic utility. Pharmaceutical companies are interested in evaluation of the therapeutic potential of targeting kinases to define new opportunities to address unmet medical needs. Lucidicor, Inc. h ...

    SBIR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government